Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis
- PMID: 20332404
- DOI: 10.1001/jama.2010.310
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis
Abstract
Context: Theory and simulation suggest that randomized controlled trials (RCTs) stopped early for benefit (truncated RCTs) systematically overestimate treatment effects for the outcome that precipitated early stopping.
Objective: To compare the treatment effect from truncated RCTs with that from meta-analyses of RCTs addressing the same question but not stopped early (nontruncated RCTs) and to explore factors associated with overestimates of effect.
Data sources: Search of MEDLINE, EMBASE, Current Contents, and full-text journal content databases to identify truncated RCTs up to January 2007; search of MEDLINE, Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects to identify systematic reviews from which individual RCTs were extracted up to January 2008.
Study selection: Selected studies were RCTs reported as having stopped early for benefit and matching nontruncated RCTs from systematic reviews. Independent reviewers with medical content expertise, working blinded to trial results, judged the eligibility of the nontruncated RCTs based on their similarity to the truncated RCTs.
Data extraction: Reviewers with methodological expertise conducted data extraction independently.
Results: The analysis included 91 truncated RCTs asking 63 different questions and 424 matching nontruncated RCTs. The pooled ratio of relative risks in truncated RCTs vs matching nontruncated RCTs was 0.71 (95% confidence interval, 0.65-0.77). This difference was independent of the presence of a statistical stopping rule and the methodological quality of the studies as assessed by allocation concealment and blinding. Large differences in treatment effect size between truncated and nontruncated RCTs (ratio of relative risks <0.75) occurred with truncated RCTs having fewer than 500 events. In 39 of the 63 questions (62%), the pooled effects of the nontruncated RCTs failed to demonstrate significant benefit.
Conclusions: Truncated RCTs were associated with greater effect sizes than RCTs not stopped early. This difference was independent of the presence of statistical stopping rules and was greatest in smaller studies.
Comment in
-
Bias and trials stopped early for benefit.JAMA. 2010 Jul 14;304(2):156; author reply 158-9. doi: 10.1001/jama.2010.930. JAMA. 2010. PMID: 20628124 No abstract available.
-
Bias and trials stopped early for benefit.JAMA. 2010 Jul 14;304(2):157-8; author reply 158-9. doi: 10.1001/jama.2010.932. JAMA. 2010. PMID: 20628125 No abstract available.
-
Bias and trials stopped early for benefit.JAMA. 2010 Jul 14;304(2):157; author reply 158-9. doi: 10.1001/jama.2010.931. JAMA. 2010. PMID: 20628126 No abstract available.
-
Bias and trials stopped early for benefit.JAMA. 2010 Jul 14;304(2):158; author reply 158-9. doi: 10.1001/jama.2010.933. JAMA. 2010. PMID: 20628127 No abstract available.
Similar articles
-
Randomized trials stopped early for benefit: a systematic review.JAMA. 2005 Nov 2;294(17):2203-9. doi: 10.1001/jama.294.17.2203. JAMA. 2005. PMID: 16264162
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.Cochrane Database Syst Rev. 2012 Nov 14;11(11):MR000030. doi: 10.1002/14651858.MR000030.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152285 Free PMC article.
-
Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. doi: 10.3310/hta11060. Health Technol Assess. 2007. PMID: 17280624
Cited by
-
Drotrecogin alfa (activated)...a sad final fizzle to a roller-coaster party.Crit Care. 2012 Feb 6;16(1):107. doi: 10.1186/cc11152. Crit Care. 2012. PMID: 22309988 Free PMC article. Review.
-
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial.PLoS Med. 2019 Sep 12;16(9):e1002901. doi: 10.1371/journal.pmed.1002901. eCollection 2019 Sep. PLoS Med. 2019. PMID: 31513665 Free PMC article. Clinical Trial.
-
Clinical relevance of nasopharyngeal SARS-CoV-2 viral load reduction in outpatients with COVID-19.J Antimicrob Chemother. 2022 Jun 29;77(7):2038-2039. doi: 10.1093/jac/dkac104. J Antimicrob Chemother. 2022. PMID: 35380667 Free PMC article. No abstract available.
-
Are investigators' access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials.BMC Med Ethics. 2021 Aug 28;22(1):115. doi: 10.1186/s12910-021-00681-9. BMC Med Ethics. 2021. PMID: 34454496 Free PMC article.
-
Glycemic Control for Patients With Type 2 Diabetes Mellitus: Our Evolving Faith in the Face of Evidence.Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):504-12. doi: 10.1161/CIRCOUTCOMES.116.002901. Epub 2016 Aug 23. Circ Cardiovasc Qual Outcomes. 2016. PMID: 27553599 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources